November 15, 2008Expert Opinion on Investigational Drugs

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

View Full Paper

Ask AI

Bookmark

Population

Patients with venous and arterial thromboembolic disease, acute coronary syndromes, and non-valvular atrial…

Design

Review

Authors

JCJennifer CarreiroNew England College JAJack AnsellPreventive Cardiology

Discussion

Member takes

Implication

This review highlights the pharmacological profile and ongoing clinical evaluation of apixaban as an alternative to warfarin for various thromboembolic indications.

Structured PICO

Population

Patients with venous and arterial thromboembolic disease, acute coronary syndromes, and non-valvular atrial fibrillation (review of ongoing trials)

Intervention

Apixaban (oral direct Factor Xa inhibitor)

This review highlights the pharmacological profile and ongoing clinical evaluation of apixaban as an alternative to warfarin for various thromboembolic indications.

Cite This Study

Carreiro et al. (2008) studied this question.

synapsesocial.com/papers/6a7ad41f77336a1bae02fd47 https://doi.org/10.1517/13543780802528625

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Implication

This review highlights the pharmacological profile and ongoing clinical evaluation of apixaban as an alternative to warfarin for various thromboembolic indications.

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider